Betty Ford and the press conference that changed oncology

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Sept. 30, 1974: NCI hits the tabloids

Spotlight article: Breast Cancer Report To The Profession Suddenly Is a Report To The Nation; Treatment Progress Noted
The Cancer Letter | Oct. 7, 1974

An NCI press conference is rarely a tabloid affair—except on Sept. 30, 1974. What was anticipated to be a dry occasion shifted when Betty Ford, wife of President Gerald Ford, underwent a radical mastectomy Sept. 28. 

The Cancer Letter was there: “Breast Cancer Report To The Profession Suddenly Is a Report To The Nation; Treatment Progress Noted,” was the Oct. 7, 1974 issue’s lead story

Nathaniel Berlin, then director of NCI’s Division of Biology & Diagnosis and chairman of the Breast Cancer Task Force, had been concerned the breast cancer report would receive limited public attention. Instead, he got a media circus—leading to fears of publishing the findings prematurely. 

No one talked about their cancer diagnosis in the 1970s. Surprisingly, Betty Ford credits Richard Nixon—in part—for her pioneering openness about her breast cancer diagnosis: 

“There had been so much cover-up during Watergate that we wanted to be sure there would be no cover-up in the Ford administration,” Betty Ford told Gloria Steinem in a 1984 interview. “So rather than continue this traditional silence about breast cancer, we felt we had to be very public.”

“Too many women are so afraid of breast cancer that they endanger their lives,” Ford said in remarks to the American Cancer Society Nov. 7, 1975. “These fears of being ‘less’ of a woman are very real, and it is very important to talk about the emotional side effects honestly. They must come out into the open.”

Betty Ford’s openness had results: “At the time of my mastectomy, I was pleased to see the response to it,” she said in 1976 at a dedication of MD Anderson facilities. “It prompted many women to get a check up.” 

This phenomenon became known as the “Betty Ford blip.”

What was her prognosis? The Cancer Letter’s 1974 article notes that “historically more than 50% of breast cancer patients die with metastatic disease…. More than 75% of patients with 1 or more positive nodes will have recurrent disease at 10yrs and most of the patients will die of their disease.” 

Betty Ford, who was found in 1974 to have four positive nodes, was prescribed an L-PAM regimen, and beat the odds. As a cancer survivor, she continued her advocacy and breast cancer awareness campaigns. 

Concluding her 1975 ACS address, Ford said, “My illness turned out to have a very special purpose—helping save other lives, and I am grateful for what I was able to do.”

Ford died in 2011 at the age of 93. A comprehensive obituary ran in Time


Recent contributions

Connie Henke Yarbro: 1984 Cancer Nursing Perspective
By Oncology Nursing Society | June 24, 2021

Women in Science: Candace Johnson, PhD
By Roswell Park Comprehensive Cancer Center | June 21, 2021


This column features the latest posts to the Cancer History Project by our growing list of contributors

The Cancer History Project is a free, web-based, collaborative resource intended to mark the 50th anniversary of the National Cancer Act and designed to continue in perpetuity. The objective is to assemble a robust collection of historical documents and make them freely available. 

Access to the Cancer History Project is open to the public at CancerHistoryProject.com. You can also follow us on Twitter at @CancerHistProj.

Is your institution a contributor to the Cancer History Project? Eligible institutions include cancer centers, advocacy groups, professional societies, pharmaceutical companies, and key organizations in oncology. 

To apply to become a contributor, please contact admin@cancerhistoryproject.com.

Katie Goldberg
Director of Operations
Table of Contents

YOU MAY BE INTERESTED IN

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

In the evolving landscape of pediatric oncology, survivorship research has become an essential component of our mission to improve long-term patient outcomes. At City of Hope, we are focused on not only curing childhood cancers but also ensuring that survivors live the healthiest lives possible. A significant part of my research has been dedicated to mitigating the long-term toxicities of cancer therapy—particularly cardiovascular complications that can arise decades after treatment.
Katie Goldberg
Director of Operations

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login